The first outbreak in Wuhan, China, in December 2019 was reported about severe acute coronaviral syndrome 2 (SARS-CoV-2). The global coronavirus disease 2019 (COVID-19) pandemic in 2020 resulted in an extremely high potential for dissemination. No drugs are validated in large-scale studies for significant effectiveness in the clinical treatment of COVID-19 patients, despite the worsening trends of COVID-19. This study aims to design a simple and efficient cyclo-condensation reaction of 6-aminouracil derivatives 2a–e and isatin derivatives 1a–c to synthesize spiro-oxindoles 3a–d, 4a–e, and 5a–e. All compounds were tested in vitro against the SARS-CoV-2. Four spiro[indoline-3,5′-pyrido[2,3-d:6,5-d’]dipyrimidine derivatives 3a, 4b, 4d, and 4e showed high activities against the SARS-CoV-2 in plaque reduction assay and were subjected to further RNA-dependent-RNA-polymerase (RdRp) and spike glycoprotein inhibition assay investigations. The four compounds exhibited potent inhibitory activity ranging from 40.23 ± 0.09 to 44.90 ± 0.08 nM and 40.27 ± 0.17 to 44.83 ± 0.16 nM, respectively, when compared with chloroquine as a reference standard, which showed 45 ± 0.02 and 45 ± 0.06 nM against RdRp and spike glycoprotein, respectively. The computational study involving the docking studies of the binding mode inside two proteins ((RdRp) (PDB: 6m71), and (SGp) (PDB: 6VXX)) and geometrical optimization used to generate some molecular parameters were performed for the most active hybrids.
2019年12月,中国武汉爆发了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。2020年,全球新冠肺炎(COVID-19)大流行导致了极高的传播潜力。尽管COVID-19的趋势不断恶化,但目前没有任何药物在大规模研究中被证明对COVID-19患者的临床治疗具有显著的有效性。本研究旨在设计一种简单高效的6-氨基尿嘧啶衍生物2a-e和吲哚酮衍生物1a-c的环缩合反应,以合成螺环氧吲哚3a-d,4a-e和5a-e。所有化合物均在体外对SARS-CoV-2进行了测试。四个螺[吲哚-3,5'-吡啶[2,3-d:6,5-d']]二嘧啶衍生物3a、4b、4d和4e在减少斑点实验中表现出高活性,并进一步进行了RNA依赖性RNA聚合酶(RdRp)和尖刺糖蛋白抑制试验的研究。与氯喹作为参考标准相比,这四种化合物在抑制RdRp和尖刺糖蛋白方面表现出强大的抑制活性,分别为40.23±0.09至44.90±0.08 nM和40.27±0.17至44.83±0.16 nM。计算研究涉及到两种蛋白内的结合模式的对接研究(RdRp(PDB:6m71)和SGp(PDB:6VXX)),并进行了一些分子参数的几何优化,以生成最活跃的杂交物。